These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

543 related articles for article (PubMed ID: 25461655)

  • 41. Successful treatment of extensively drug-resistant Acinetobacter baumannii peritoneal dialysis peritonitis with intraperitoneal polymyxin B and ampicillin-sulbactam.
    Fitzpatrick MA; Esterly JS; Postelnick MJ; Sutton SH
    Ann Pharmacother; 2012; 46(7-8):e17. PubMed ID: 22811349
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Urinary Concentrations of Colistimethate and Formed Colistin after Intravenous Administration in Patients with Multidrug-Resistant Gram-Negative Bacterial Infections.
    Luque S; Escaño C; Sorli L; Li J; Campillo N; Horcajada JP; Salas E; Grau S
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559275
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Polymyxins for the treatment of extensively-drug-resistant Gram-negative bacteria: from pharmacokinetics to bedside.
    Zavascki AP
    Expert Rev Anti Infect Ther; 2014 May; 12(5):531-3. PubMed ID: 24666285
    [TBL] [Abstract][Full Text] [Related]  

  • 44. In vivo activity of daptomycin/colistin combination therapy in a Galleria mellonella model of Acinetobacter baumannii infection.
    Yang H; Chen G; Hu L; Liu Y; Cheng J; Li H; Ye Y; Li J
    Int J Antimicrob Agents; 2015 Feb; 45(2):188-91. PubMed ID: 25440154
    [TBL] [Abstract][Full Text] [Related]  

  • 45. International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP).
    Tsuji BT; Pogue JM; Zavascki AP; Paul M; Daikos GL; Forrest A; Giacobbe DR; Viscoli C; Giamarellou H; Karaiskos I; Kaye D; Mouton JW; Tam VH; Thamlikitkul V; Wunderink RG; Li J; Nation RL; Kaye KS
    Pharmacotherapy; 2019 Jan; 39(1):10-39. PubMed ID: 30710469
    [TBL] [Abstract][Full Text] [Related]  

  • 46. In vivo activity of vancomycin combined with colistin against multidrug-resistant strains of Acinetobacter baumannii in a Galleria mellonella model.
    Yang H; Lv N; Hu L; Liu Y; Cheng J; Ye Y; Li J
    Infect Dis (Lond); 2016; 48(3):189-94. PubMed ID: 26503239
    [TBL] [Abstract][Full Text] [Related]  

  • 47. In Vitro Activities of Novel Antimicrobial Combinations against Extensively Drug-Resistant Acinetobacter baumannii.
    Córdoba J; Coronado-Álvarez NM; Parra D; Parra-Ruiz J
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7316-9. PubMed ID: 26369956
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Rifampicin as adjunct to colistin therapy in the treatment of multidrug-resistant Acinetobacter baumannii.
    Al-Shaer M; Nazer LH; Kherallah M
    Ann Pharmacother; 2014 Jun; 48(6):766-71. PubMed ID: 24651164
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Synergistic effect between nisin and polymyxin B against pandrug-resistant and extensively drug-resistant Acinetobacter baumannii.
    Thomas VM; Brown RM; Ashcraft DS; Pankey GA
    Int J Antimicrob Agents; 2019 May; 53(5):663-668. PubMed ID: 30880230
    [TBL] [Abstract][Full Text] [Related]  

  • 50. fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models.
    Dudhani RV; Turnidge JD; Nation RL; Li J
    J Antimicrob Chemother; 2010 Sep; 65(9):1984-90. PubMed ID: 20573659
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The 21st-century challenge to neurocritical care: the rise of the superbug Acinetobacter baumannii. A meta-analysis of the role of intrathecal or intraventricular antimicrobial therapy in reduction of mortality.
    Mohammed N; Savardekar AR; Patra DP; Narayan V; Nanda A
    Neurosurg Focus; 2017 Nov; 43(5):E8. PubMed ID: 29088961
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Nephrotoxicity of Polymyxins: Is There Any Difference between Colistimethate and Polymyxin B?
    Zavascki AP; Nation RL
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 27993859
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Colistin: understanding and applying recent pharmacokinetic advances.
    Ortwine JK; Kaye KS; Li J; Pogue JM
    Pharmacotherapy; 2015 Jan; 35(1):11-6. PubMed ID: 25187500
    [TBL] [Abstract][Full Text] [Related]  

  • 54. High-Dose Ampicillin-Sulbactam Combinations Combat Polymyxin-Resistant Acinetobacter baumannii in a Hollow-Fiber Infection Model.
    Lenhard JR; Smith NM; Bulman ZP; Tao X; Thamlikitkul V; Shin BS; Nation RL; Li J; Bulitta JB; Tsuji BT
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28052852
    [No Abstract]   [Full Text] [Related]  

  • 55. Detection of colistin heteroresistance in Acinetobacter baumannii from blood and respiratory isolates.
    Srinivas P; Hunt LN; Pouch SM; Thomas K; Goff DA; Pancholi P; Balada-Llasat JM; Bauer KA
    Diagn Microbiol Infect Dis; 2018 Jun; 91(2):194-198. PubMed ID: 29482871
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Strategies for the treatment of polymyxin B-resistant Acinetobacter baumannii infections.
    Menegucci TC; Albiero J; Migliorini LB; Alves JL; Viana GF; Mazucheli J; Carrara-Marroni FE; Cardoso CL; Tognim MC
    Int J Antimicrob Agents; 2016 May; 47(5):380-5. PubMed ID: 27068675
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical translation of polymyxin-based combination therapy: Facts, challenges and future opportunities.
    Zhang X; Guo F; Shao H; Zheng X
    J Infect; 2017 Feb; 74(2):118-130. PubMed ID: 27998750
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Polymyxin Resistance in Acinetobacter baumannii: Genetic Mutations and Transcriptomic Changes in Response to Clinically Relevant Dosage Regimens.
    Cheah SE; Johnson MD; Zhu Y; Tsuji BT; Forrest A; Bulitta JB; Boyce JD; Nation RL; Li J
    Sci Rep; 2016 May; 6():26233. PubMed ID: 27195897
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines.
    Gales AC; Reis AO; Jones RN
    J Clin Microbiol; 2001 Jan; 39(1):183-90. PubMed ID: 11136768
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antibiograms of multidrug-resistant clinical Acinetobacter baumannii: promising therapeutic options for treatment of infection with colistin-resistant strains.
    Li J; Nation RL; Owen RJ; Wong S; Spelman D; Franklin C
    Clin Infect Dis; 2007 Sep; 45(5):594-8. PubMed ID: 17682994
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.